OR WAIT null SECS
Article
Results from the EAGLE and ZAP clinical trials provide answers to lingering questions.
Study: Neurolenses significantly impact reading speed
FDA approves biosimilar product ranibizumab-eqrn for retinal diseases
Aerie doses first patient in COMET-3 study for DED treatment
EyeCare4Kids names new executive director